α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia

被引：46
|
作者：
Ishikawa, Masatomo [1 ]
Hashimoto, Kenji [1 ]
机构：
[1] Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba 2608670, Japan
来源：
CURRENT PHARMACEUTICAL DESIGN | 2011年 / 17卷 / 02期
关键词：
alpha 7 nicotinic acetylcholine receptors; schizophrenia; smoking; nicotine; P50 auditory evoked potential suppression; agonists; allosteric modulators; VITRO PHARMACOLOGICAL CHARACTERIZATION; POSITIVE ALLOSTERIC MODULATOR; INDUCED COGNITIVE DEFICITS; REPEATED AUDITORY-STIMULI; IN-VIVO CHARACTERIZATION; MIDBRAIN DOPAMINE AREAS; CIGARETTE-SMOKING; P50; SUPPRESSION; PARTIAL AGONIST; DBA/2; MICE;
D O I：
10.2174/138161211795049561
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Accumulating evidence suggests that the alpha 7 subtype of nicotinic acetylcholine receptors (nAChRs) plays a role in the pathophysiology of schizophrenia. Deficits in auditory P50 evoked potential suppression in patients with schizophrenia are associated with decreased density of alpha 7 nAChRs in the brain. Some agonists (e. g., DMXB-A and tropisetron) at alpha 7 nAChRs can improve P50 deficits in patients with schizophrenia. Together, these findings indicate that alpha 7 nAChRs are a potential therapeutic target for schizophrenia. Currently, a number of agonists and allosteric modulators at alpha 7 nAChRs are under development as potential therapeutic drugs. In this article, we review recent topics on alpha 7 nAChR agonists and alpha 7 nAChR allosteric modulators as therapeutic drugs for schizophrenia.
引用
收藏
页码：121 / 129
页数：9
相关论文
共 50 条
  • [21] Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits
    Stevens, Karen E.
    Zheng, Lijun
    Floyd, Kirsten L.
    Stitzel, Jerry A.
    BRAIN RESEARCH, 2015, 1611 : 8 - 17
  • [22] Physiologic Functions and Therapeutic Applications of α7 Nicotinic Acetylcholine Receptor in Brain Disorders
    Lee, Chien-Hsing
    Hung, Shih-Ya
    PHARMACEUTICS, 2023, 15 (01)
  • [23] A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists
    Buccafusco, Jerry J.
    Terry, Alvin V., Jr.
    BIOCHEMICAL PHARMACOLOGY, 2009, 78 (07) : 852 - 862
  • [24] Association of the 5′-upstream regulatory region of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia
    Stephens, Sarah H.
    Logel, Judith
    Barton, Amanda
    Franks, Alexis
    Schultz, Jessica
    Short, Margaret
    Dickenson, Jane
    James, Benjamin
    Fingerlin, Tasha E.
    Wagner, Brandie
    Hodgkinson, Colin
    Graw, Sharon
    Ross, Randal G.
    Freedman, Robert
    Leonard, Sherry
    SCHIZOPHRENIA RESEARCH, 2009, 109 (1-3) : 102 - 112
  • [25] Nicotinic Modulation of Innate Immune Pathways Via α7 Nicotinic Acetylcholine Receptor
    Cui, Wen-Yan
    Li, Ming D.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2010, 5 (04) : 479 - 488
  • [26] Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia
    Young, Jared W.
    Geyer, Mark A.
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (08) : 1122 - 1132
  • [27] Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
    Jones, Carrie K.
    Byun, Nellie
    Bubser, Michael
    NEUROPSYCHOPHARMACOLOGY, 2012, 37 (01) : 16 - 42
  • [28] The α7 nicotinic acetylcholine receptor in schizophrenia:: decreased mRNA levels in peripheral blood lymphocytes
    Perl, O
    Ilani, T
    Strous, RD
    Lapidus, R
    Fuchs, S
    FASEB JOURNAL, 2003, 17 (11) : 1948 - +
  • [29] Consequences of low levels of nicotinic acetylcholine receptors in schizophrenia for drug development
    Leonard, S
    DRUG DEVELOPMENT RESEARCH, 2003, 60 (02) : 127 - 136
  • [30] Neuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Acetylcholine the Alpha-7 nicotinic Acetylcholine Receptor
    das Gracas Corsi-Zuelli, Fabiana Maria
    Brognara, Fernanda
    da Silva Quirino, Gustavo Fernando
    Hiroki, Carlos Hiroji
    Fais, Rafael Sobrano
    Del-Ben, Cristina Marta
    Ulloa, Luis
    Salgado, Helio Cesar
    Kanashiro, Alexandre
    Loureiro, Camila Marcelino
    FRONTIERS IN IMMUNOLOGY, 2017, 8
12345